AI-driven drug design from molecule to clinical candidate
Exscientia is an AI-powered drug discovery and design platform for pharmaceutical research.
AI Panel Score
6 AI reviews
Reviewed
Exscientia is a UK-based AI-first drug discovery company that develops proprietary technology to design and optimize small molecule drug candidates. The platform integrates machine learning models with experimental data to predict molecular properties, enabling researchers to explore chemical space more efficiently than traditional methods. Its end-to-end approach covers target identification, hit discovery, lead optimization, and candidate selection.
The company operates a hybrid model, maintaining its own internal pipeline of therapeutic programs while also partnering with major pharmaceutical and biotechnology companies. Partners have included Sanofi, Bristol Myers Squibb, and Bayer, among others. These collaborations typically involve applying Exscientia's AI platform to a partner's therapeutic targets in exchange for milestone payments and royalties.
A notable aspect of Exscientia's approach is its use of closed-loop automation, where AI-designed molecules are synthesized and tested by robotic systems, and the resulting experimental data feeds back into the models. This iterative cycle is designed to accelerate candidate progression timelines significantly compared to conventional drug discovery workflows.
Exscientia has reported moving several drug candidates into clinical trials, positioning itself as one of the further-advanced AI drug discovery companies in terms of pipeline progression. Its technology is aimed at drug hunters, medicinal chemists, and biopharma R&D organizations looking to improve the efficiency and success rate of early-stage drug development.
As a company rather than a conventional software-as-a-service product, Exscientia does not publicly list subscription pricing. Access to its platform and capabilities is typically negotiated through enterprise partnerships or collaborations rather than self-service plans.
Designs highly optimized molecules using AI models trained on proprietary biological and chemical datasets to fuel a pipeline of potential first-in-class and best-in-class medicines.
Uses images of cells to train artificial intelligence models that identify cellular disruptions driving disease across vast unknown biological space.
Trains intelligent machine learning models to rapidly identify new biological targets for drug discovery and development.
Incorporates de-identified patient data into the discovery platform to enhance AI model training and improve drug development insights.
Aggregates over 50 petabytes of fit-for-purpose data spanning phenomics, transcriptomics, proteomics, ADME, and de-identified patient data to power drug discovery models.
Utilizes robotics and computer vision to capture millions of cell experiments per week, enabling rapid generation of experimental data.
Enables strategic partnerships with pharmaceutical industry leaders, computational technology companies, and next-generation data partners to accelerate drug discovery and expand patient impact.
A biopharma supercomputer built in partnership with NVIDIA, designed to process the massive biological and chemical datasets used across the Recursion OS platform.
Tracks and manages an advanced pipeline of therapeutic candidates across Oncology and Rare Disease indications from Preclinical through Phase 3 stages.
An integrated drug discovery and development platform that connects data, AI models, and compute in a continuously improving feedback loop from hit identification to IND-enabling studies.
Exscientia operates as a drug-discovery partner rather than a self-serve SaaS — engagements are structured as multi-year discovery collaborations or platform licensing deals. Contact the business-development team for terms.
Exscientia is now Recursion — evaluate the combined balance sheet, not the legacy AI drug-design brand.
“Exscientia closed its all-stock merger with Recursion in 2024, valued at roughly $193 million, and now operates inside Recursion Pharmaceuticals. The combined company is publicly traded with cash runway guided into 2027.”
Three questions before this review even matters. Did the 2024 Recursion merger close? Yes. Is Exscientia still an independent vendor? No. Is the combined company worth a 36-month bet? That's the actual conversation.
Recursion OS is the asset you're actually licensing — closed-loop AI design feeding a wet lab that captures millions of cell experiments weekly, all crunched on BioHive-2, the NVIDIA-built supercomputer. Sanofi signed for $100 million upfront and up to $5.2 billion in milestones in 2022. That's the validation Schrödinger and Insilico Medicine still chase.
But this isn't software you procure. There's no pricing page, no self-serve tier — engagements are multi-year discovery partnerships negotiated by BD. Pilot a single target program before anyone talks about platform licensing, and watch the cash runway, which management has guided into 2027.
Most pipeline-advanced AI drug discovery platform; ahead of Schrödinger and Insilico on clinical progression.
Sanofi, BMS, Bayer, and NVIDIA collaborations make the choice defensible to any pharma board.
Drug discovery cycles measured in years; no quarterly payback even with closed-loop automation.
Genuine fit for pharma R&D buyers seeking AI-led discovery partners, less so for software procurement.
Combined Recursion-Exscientia entity reported ~$850M cash post-merger with guided runway into 2027.
Biopharma R&D leaders who want a discovery partner backed by public-company disclosure.
Software buyers expecting a SaaS tier or a self-serve trial.
Two AI drug-discovery pipelines under one Recursion OS — the moat is data scale, not molecule design.
“Recursion closed the $688M all-stock Exscientia acquisition in late 2024, inheriting REC-3565 MALT1 and REC-4539 LSD1 alongside its own RBM39 program REC-1245. The catch is that closed-loop AI discovery still has to clear Phase 2 readouts — Insilico Medicine and Isomorphic Labs are racing the same clock.”
Recursion finished absorbing Exscientia in late 2024, an all-stock deal valued near $688M, leaving roughly $850M cash and a projected $100M in annual synergies. Exscientia's REC-3565 MALT1 and REC-4539 LSD1 began Q1 2025 dosing, joining Recursion's REC-1245 RBM39 degrader.
Recursion OS is the integrating layer — phenomics, transcriptomics, proteomics and de-identified patient data on the same substrate, with BioHive-2 (built with NVIDIA in 2024) running the models. 50 petabytes of fit-for-purpose data is the moat against Insilico Medicine's Pharma.AI and Isomorphic Labs, neither of which owns a closed-loop wet lab at this image-throughput scale.
However, the three-year call is biology, not software. Recursion deprioritized REC-4881 in 2024 and surviving oncology programs are still early Phase 1; no AI-discovered molecule has cleared Phase 3 anywhere in the category. The bet is whether closed-loop phenomics shortens cycles before pipeline attrition forces another consolidation.
Post-merger, the combined company is the most-capitalized public AI drug discovery platform with $850M cash and a four-program oncology pipeline.
Enterprise discovery-partnership model with Sanofi, Bristol Myers Squibb and Bayer matches how biopharma R&D actually procures platform tech.
Partnership-only access fits pharma enterprise stacks but rules out self-serve integration for smaller biotech teams.
Recursion OS lock-in is real and pipeline still has to deliver Phase 2 wins before the architecture pays off.
BioHive-2 with NVIDIA plus 50 petabytes of phenomics, transcriptomics and ADME data is best-in-class craft depth for AI drug discovery.
Biopharma R&D leaders who need closed-loop AI discovery at petabyte data scale.
Solo researchers who want a self-serve molecular design tool.
Recursion absorbed Exscientia in a $193M all-stock deal November 2024 — no standalone SKU survives.
“No published pricing — Exscientia engagements now invoice through Recursion Pharmaceuticals as multi-year discovery partnerships. Sanofi's 2022 deal anchors the comp at $100M upfront against $5.2B in clinical milestones.”
Recursion absorbed Exscientia in a $193M all-stock deal closed November 2024. There is no Exscientia SKU anymore — the platform invoices through Recursion Pharmaceuticals. Public NASDAQ counterparty under ticker RXRX, audited financials, real cap table. Procurement at least gets a real legal entity.
No published pricing. Engagements run as multi-year discovery partnerships, milestone-plus-royalty paper. Sanofi's 2022 deal anchors the comp — $100M upfront, up to $5.2B across 15 small-molecule programs. Most biotechs will not see that scale. Mid-size buyers negotiate target-by-target.
Recursion OS and the NVIDIA-built BioHive-2 supercomputer with 504 H100 GPUs are real assets. Compare to Isomorphic Labs — Google-backed, partnership-only, similar gating on access. But the catch is ROI on a discovery deal does not land for five to seven years. Milestones tie to clinical phases, not quarterly budget reviews.
NASDAQ-listed counterparty (RXRX) with audited financials reduces legal-entity vendor risk.
Multi-year discovery partnerships with milestone-plus-royalty paper, negotiable per deal but not standardized.
No published pricing anywhere — every engagement requires a business-development sales call.
Discovery ROI tied to clinical phases over five to seven years, not quarterly metrics.
Sanofi anchor is $100M upfront against $5.2B milestones across 15 programs — most buyers cannot model their own version.
Biopharma R&D leaders who need AI-driven small-molecule discovery.
SMB buyers who need self-serve SaaS pricing.
Centaur Chemist designs molecules a med chem team can defend, but the platform now lives inside Recursion.
“Exscientia's Centaur Chemist platform compresses lead optimization by scoring potency, selectivity, and ADME in one design pass instead of three separate assay rounds. After the November 2024 Recursion merger, the tool is no longer accessible as a standalone partnership — it ships as part of Recursion OS.”
Centaur Chemist scores potency, selectivity, ADME, and synthetic tractability in one multi-parameter pass — work a med chem team normally splits across three weekly assay reviews. DSP-1181 with Sumitomo Dainippon reached candidate after about 350 compounds, versus the roughly 2,500 a conventional program burns through. That's the number every deck cites.
The closed loop matters in practice. Designs go to the automated wet lab, synthesis and assays run, results feed the next iteration — no chemist hand-copying CSVs into Schrödinger LiveDesign. Atomwise stayed virtual-screen-only; Exscientia owned the synthesis loop, which is where most AI design platforms fall over.
But after the November 2024 Recursion merger, Exscientia stopped existing as a standalone partner. Centaur Chemist now ships inside Recursion OS alongside BioHive-2. Chemists who just wanted the small-molecule design layer are buying into a phenomics-first platform.
Closed-loop design-make-test is real, but post-merger practitioner access runs through Recursion business development.
Public technical material is limited to SEC filings, partner press releases, and a handful of conference papers.
No self-serve entry — every engagement is a multi-year discovery collaboration negotiated through sales.
Multi-parameter optimization across potency, selectivity, ADME, and tractability is genuinely deep for a chemistry workflow.
Owns the synthesis loop end-to-end, eliminating CSV handoffs to external design tools like Schrödinger LiveDesign.
Medicinal chemists who want closed-loop AI design tied to automated synthesis.
Teams who need standalone small-molecule tooling without committing to Recursion OS.
Exscientia is a tab on Recursion's website now, and the merger price was $193 million in stock.
“Recursion absorbed Exscientia in 2024 for about $193 million all-stock, and the combined company runs as Recursion Pharmaceuticals. The platform is enterprise-only — partnerships and licensing deals, no self-serve, no pricing page.”
The link from this page lands you on recursion.com. The Exscientia name lives on press releases and SEC filings, but the product is the Recursion OS now. One company's stack, another's brand on the side.
The technical bench is real. BioHive-2, the NVIDIA H100 supercomputer they stood up in 2024, hit #35 on the TOP500 list and runs four times faster than BioHive-1. A 50-petabyte phenomics dataset is the moat. Schrödinger sells chemistry simulation software, not 2 million wet-lab experiments a week feeding the models.
But there's no product to buy. No pricing tier, no trial, no docs — just a contact button and a multi-year discovery collaboration on the other side. Mobile is moot when there's no app at all; the whole platform is web-only and behind enterprise sales. Day three for a researcher means MSA negotiation, not a sandbox.
Website and brand collateral are clean post-merger, though Exscientia-branded pages now redirect to Recursion.
No public docs or changelog; the platform is taught through partner engagements, not self-discovery.
Neutral score for enterprise scientific infrastructure where mobile is not a relevant surface.
There is no onboarding — every engagement starts with a contact-sales button and a partnership conversation.
BioHive-2 with 504 NVIDIA H100 GPUs and multi-year deals with Sanofi, Bayer, and Roche signal a real operating bench.
Pharma R&D teams who can sign multi-year discovery deals.
Solo researchers who need self-serve access today.
Recursion absorbed Exscientia in an all-stock deal valued at $193M in August 2024.
“Exscientia closed into Recursion Pharmaceuticals last year, and the platform now ships under the Recursion OS banner with BioHive-2 compute behind it. The AI drug-design pitch is real, but the standalone Exscientia thesis is gone.”
The brand on the door says Exscientia. The website redirects to Recursion. That's the first thing to know — the all-stock merger closed in 2024 at roughly $193M, and Exscientia shareholders ended up with 26% of the combined entity. Not the merger of equals it was sold as.
What survived is the platform. Recursion OS now sits on 50 petabytes of phenomics and ADME data, BioHive-2 runs the compute via NVIDIA, and the closed-loop wet lab keeps shipping experimental cycles weekly. Real infrastructure, not a slide deck.
But the clinical scoreboard is mixed. DSP-1181, the AI-designed OCD candidate Exscientia trumpeted in 2020, was discontinued by Sumitomo by 2022. Isomorphic Labs has Alphabet money and DeepMind talent. Insilico Medicine has more Phase 2 readouts. The platform is durable; the differentiation isn't obvious anymore.
Real wet-lab plus compute moat, but Isomorphic Labs and Insilico Medicine crowd the same pitch.
Discovery partnership engagements are not extractable software; you exit by ending the contract.
Combined entity held roughly $850M cash at close with runway into 2027 and public-market discipline.
Product page still markets Exscientia, but the URL and brand have already shifted to Recursion post-merger.
DSP-1181 discontinuation and the absorbed-by-acquirer pattern mirror earlier struggling AI-bio cohort.
Pharma R&D teams who want a multi-year discovery collaboration with embedded AI design and wet-lab cycles.
Biotech buyers who need self-serve software or short engagement contracts.
Common questions answered by our AI research team
Exscientia applies AI-driven molecular design to accelerate drug discovery, combining machine learning with robotic laboratory automation to design and optimize drug candidates faster and at lower cost than traditional methods.
Yes, Exscientia combines AI-driven molecular design with robotic laboratory automation, integrating computational and physical lab processes to streamline preclinical drug development.
Exscientia covers drug development from target identification through preclinical candidate selection, spanning the early discovery phases before clinical trials begin.
Yes, Exscientia partners with major pharmaceutical companies alongside developing its own internal drug pipeline.
Exscientia's core mission is to use AI and automation to radically reduce the time and cost of developing new medicines, addressing the high failure rates of traditional drug discovery.
Exscientia was an Oxford-based AI drug discovery company using machine learning to design novel small molecules, acquired by Recursion in October 2024.
